The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
TRY: A phase II study to evaluate safety and efficacy of combined trastuzumab and AUY922 in advanced non-small cell lung cancer (NSCLC) with HER2 overexpression or amplification or mutation.
Lucia Nogova
Consultant or Advisory Role - Amgen; Roche
Honoraria - Amgen; Boehringer Ingelheim; Roche
Other Remuneration - Bayer; Lilly; Novartis; Pfizer
Masyar Gardizi
No relevant relationships to disclose
Marc Christiaan Allardt Bos
No relevant relationships to disclose
Matthias Scheffler
No relevant relationships to disclose
Christian Mattonet
No relevant relationships to disclose
Lukas Carl Heukamp
Consultant or Advisory Role - Qiagen
Honoraria - Novartis; Roche
Research Funding - Novartis
Other Remuneration - Novartis; Roche
Hans-Ulrich Schildhaus
No relevant relationships to disclose
Uwe Fuhr
No relevant relationships to disclose
Wilfried Eberhardt
Consultant or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; GlaxoSmithKline; Lilly; Novartis; Pfizer; Roche
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; GlaxoSmithKline; Hexal; Lilly; Novartis; Pfizer; Roche; Teva
Research Funding - Lilly
Henning Reis
No relevant relationships to disclose
Marcel Wiesweg
No relevant relationships to disclose
Kurt Werner Schmid
No relevant relationships to disclose
Gernot Schoch
No relevant relationships to disclose
Yon-Dschun Ko
No relevant relationships to disclose
Monika Heidi Serke
No relevant relationships to disclose
Martin H. Schuler
Consultant or Advisory Role - Novartis; Roche
Honoraria - Novartis
Research Funding - Novartis
Reinhard Buettner
Honoraria - Lilly; Merck; Novartis; Pfizer; Qiagen; Roche
Juergen Wolf
Consultant or Advisory Role - Novartis; Roche
Honoraria - Novartis; Roche
Research Funding - Novartis; Roche